Authors
Latest:
Future Directions in PSMA-PET ImagingLooking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.
Latest:
13 tips to keep your patient data safe from hackersHere are 13 cybersecurity measures medical practices can take to protect patient data from hackers.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Practice Management: Expert coding tipsA physician’s goal is to care for patients, but a key part of being able to provide that care is the eternal quest for payment.
Latest:
Gopa Iyer, MD, highlights SURF301 trial of TYRA-300 in mUC"The preliminary results of that study, which is a phase 1/2 dose escalation and dose expansion trial, were presented by Professor Ben Tran last year at the ENA meeting1 and showed a very favorable toxicity profile compared to erdafitinib," says Gopa Iyer, MD.
Latest:
Vaginal prolapse repair and sling surgery significantly reduce UUI"The biggest message from this study is that 60% can expect resolution of UUI, simply by fixing the prolapse and placing a sling, which is not normally indicated for UUI," according to Christina M. Mezes, DO, and Catherine A. Matthews, MD.
Latest:
Managing BCG-Unresponsive NMIBC: Cretostimogene Monotherapy vs. Combination TherapyPanelists discuss their views on using cretostimogene as monotherapy versus combination therapy, the importance for urologists to stay updated on advances for managing BCG-unresponsive NMIBC, and the potential impact of combining cretostimogene with pembrolizumab on addressing unmet needs in NMIBC care.
Latest:
Upper tract urothelial carcinoma case illustrates rapidly changing treatment landscapeUrologists and medical oncologists should collaborate to tailor therapy to the specific needs of the patient.
Latest:
Management of recurrent prostate cancer after focal therapyProviders must carefully consider treatment options to align with patient preference.
Latest:
Cutting drug costs for patients: key takeaways for urologists"The Inflation Reduction Act was a major step in the right direction. The question now is going to be, are commercial insurers going to follow Medicare and enact the same cap that they have as well," says Benjamin Pockros, MD, MBA.
Latest:
Ronney Abaza, MD, on robotic surgery at ultralow pressures“In that randomized trial, we have level 1 evidence showing that patients have less pain and faster return of bowel function when you work at low pressure,” says Ronney Abaza, MD.
Latest:
Fertility preservation in patients with testicular cancer"Full discussion of the various fertility preservation options and an understanding of the fertility implications of the various treatment modalities must be understood by patients for them to make optimal decisions for their reproductive futures," write the authors.
Latest:
What is needed to advance the use of natural products in prostate cancer?"The most critical next step is to focus on enhancing both the scientific rigor of our clinical trials and the personalization of our treatment," says Channing J. Paller, MD.
Latest:
Urology Practice advice: Real estate pitfalls to avoidCommercial real estate can be one of the highest expenses for health care practices.
Latest:
Exciting Prospects for the Future of Localized Prostate Cancer TreatmentDr Mark Emberton shares what developments are visible on the horizon and what they represent for the future of focal therapy and treatment of clinically localized prostate cancer.
Latest:
Unmet Needs for the Treatment of Enteric HyperoxaluriaDr. Kyle Wood discusses optimal avenues to increase patient and provider education on enteric hyperoxaluria and provides closing thoughts on the future management of enteric hyperoxaluria.
Latest:
What a long-term study of patients undergoing RARC reveals about upstaging“High risk, non–muscle invasive bladder cancer carries a significant risk of recurrence and progression. This emphasizes the need for careful patient selection, especially when we are considering bladder-sparing approaches," says Neeraja Tillu, MD.
Latest:
A Look Into The Future of PSMA-Targeted Therapies in Prostate CancerPanelists review the recent FDA approval of the PSMA-targeted therapy Lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer and discuss additional settings in which it, and other PSMA-targeted treatments, might be used in the future.
Latest:
Future Landscape of Prostate Cancer and Rectal SpacersThe expert panel concludes their discussion with a look toward the future of prostate cancer treatment and the evolving role of rectal spacers.
Latest:
Adam Lorentz, MD, on predictions for future advances in robotics“Then recently, of course, with the single-port device, that has truly allowed us to be less invasive with our robotic approaches,” says Adam Lorentz, MD, FACS.
Latest:
BCG-unresponsive NMIBC: Current evidence and optionsMultiple investigational agents have been developed and are being studied.
Latest:
Future of Overactive Bladder TreatmentDrs MacDiarmid and Rogers discuss barriers to OAB treatments and therapies on the horizon.
Latest:
Case 4: Metastatic Castration-Resistant Prostate Cancer With an HRR AlterationPanelists discuss how the management of metastatic castration-resistant prostate cancer with a homologous recombination repair (HRR) alteration involves targeted therapies, such as PARP inhibitors, to exploit the genetic vulnerability and improve treatment response.
Latest:
Urologist discusses when to say “no” as a professional"Saying 'no' is one of our biggest challenges in our careers as physicians," according to Phillip M. Pierorazio, MD.
Latest:
A primer on DNA sequencing for the practicing urologistEmbracing and understanding new and emerging molecular techniques will improve patient outcomes.
Latest:
Ernest Morton, MD, shares initial findings on the use of an AI scribe“Physicians are spending, depending on how much they utilize it, 20% to 30% less time on nights and weekends,” says Ernest A. Morton, MD, MBA, MS.
Latest:
Reining in the administrative burden in health careDoctors and medical practices are mired in administrative tasks.
Latest:
Congress to again consider prior authorization reform legislationThe bill has a mass of legislative supporters – at least 41 senators and 127 representatives, along with more than 370 organizations representing patients, physicians, hospitals and Medicare Advantage plans.
Latest:
Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCCThe phase 2 STARLITE 2 trial is assessing 177Lu-girentuximab plus nivolumab in advanced clear cell renal cell carcinoma.
Latest:
3D bioprinting technology facilitates development of an in vitro biomimetic bladder model"This exciting and innovative technology has a wide range of possible applications, including tissue engineering, drug development, and precision medicine," write Kate Gessner, MD, PhD, and Philip Abbosh, MD, PhD.
